Viking Stock: The cruise leader gave up a key benchmark this past week during the ongoing stock market weakness.

This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.

Viking Therapeutics, Inc. stock has surged nearly 1,500% since 2023, driven by the promising GLP-1/GIP receptor agonist VK-2735 for obesity. VK-2735's Phase 2 data showed weight loss comparable to ...

Looking back on consumer discretionary - travel and vacation providers stocks’ Q4 earnings, we examine this quarter’s best ...

Viking Therapeutics is developing drugs for obesity and non-alcoholic fatty liver disease. The company has no revenue and may have none for several years as it works to get drug approval. Viking could ...

Each of these companies could benefit from this high-growth market over time.

Financial giants have made a conspicuous bullish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics VKTX revealed 12 unusual trades. Delving into the details, we ...

GIP obesity drug enters Phase 3 with strong cash runway, but rising competition and trial risk. Click for this VKTX update.

Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX). And retail traders should know. We noticed this today when the positions showed up on publicly ...

CHARLOTTE, N.C., Jan. 27, 2025 /PRNewswire/ -- Viking Mergers & Acquisitions celebrated a highly successful Q4 in 2024, closing 19 deals on behalf of its clients with a total transaction value of $115 ...